TGV-Biomed is focused on the development of novel, diagnostics to select better treatments being evaluated for treating diabtetic foot ulcers. We have made life-changing breakthrough discoveries that can bring therapy of these infections to a new level of efficacy. It is our responsibility to accelerate way from our innovation to medicines thus new therapeutics not be late and be on time enhancing and extending patients’ lives.


AtbFinder is the only AST candidate that helps to select antibiotics active against all major bacterial and fungal pathogens including their multiresistant variants that are the causative agents of diabetic foot infectinos. Initial testing indicates AtbFinder to be a significant breakthrough in the war on diabtic foot infections and can help to dramatically decrease the mortality from this disease and prevent amputations.